Latest Ratios: P/E Ratio -0.1x · EV/EBITDA N/A · ROE N/A. (2011–2024 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $4M | $15M | $19M | $17M | $240M | $589M | $360M | $257M | $182M | $269M | $288M |
| Enterprise Value | $136592 | $11M | $15M | $120M | $298M | $646M | $335M | $228M | $165M | $216M | $266M |
| P/E Ratio → | -0.12 | — | 0.79 | — | — | — | — | — | — | — | — |
| P/S Ratio | 0.55 | 1.90 | 2.90 | 0.28 | 2.80 | 9.15 | 57.30 | 30.70 | 45.30 | 2667.82 | 95921.65 |
| P/B Ratio | — | — | 9.14 | — | 27.05 | 42.46 | 6.01 | 5.01 | 4.03 | 4.30 | 4.79 |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.37 | 2.22 | 1.94 | 3.48 | 10.04 | 53.29 | 27.23 | 41.19 | 2135.28 | 88749.65 |
| EV / EBITDA | — | — | 0.99 | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | 0.60 | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.3% | 60.3% | 47.0% | 46.1% | 42.4% | 42.7% | 64.1% | 66.1% | 46.9% | -30140.6% | -733300.0% |
| Operating Margin | -181.7% | -181.7% | 193.4% | -69.3% | -94.6% | -99.0% | -686.7% | -470.5% | -1297.0% | -30240.6% | -733400.0% |
| Net Profit Margin | -102.8% | -102.8% | 366.2% | -116.0% | -114.0% | -118.4% | -672.5% | -464.4% | -1136.6% | -29079.2% | -703000.0% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | 1155.9% | — | -859.7% | -206.2% | -76.1% | -80.7% | -84.5% | -47.8% | -49.6% |
| ROA | -40.2% | -40.2% | 26.3% | -42.2% | -54.1% | -59.9% | -62.0% | -64.8% | -69.2% | -41.6% | -44.1% |
| ROIC | — | — | 36.4% | -52.9% | -87.8% | -89.9% | -113.7% | -116.2% | -207.7% | -96.5% | -57.2% |
| ROCE | — | — | 332.0% | -140.2% | -78.5% | -74.7% | -74.8% | -80.6% | -90.9% | -46.9% | -49.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | 0.57 | — | 9.89 | 6.27 | 0.06 | — | — | — | — |
| Debt / EBITDA | — | — | 0.08 | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | -2.12 | — | 6.57 | 4.16 | -0.42 | -0.57 | -0.37 | -0.86 | -0.36 |
| Net Debt / EBITDA | — | — | -0.30 | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -265.69 | -265.69 | 34.42 | -1.04 | -4.90 | -5.12 | -98.31 | -235.51 | -674.96 | -4363.29 | -1833.50 |
Net cash position: cash ($5M) exceeds total debt ($356000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.54 | 0.54 | 0.84 | 0.44 | 1.09 | 0.96 | 5.01 | 5.47 | 4.37 | 12.66 | 10.97 |
| Quick Ratio | 0.37 | 0.37 | 0.61 | 0.38 | 0.91 | 0.87 | 4.84 | 5.40 | 4.31 | 12.45 | 17.23 |
| Cash Ratio | 0.21 | 0.21 | 0.33 | 0.10 | 0.47 | 0.41 | 4.51 | 5.12 | 3.91 | 12.35 | 10.54 |
| Asset Turnover | — | 0.45 | 0.28 | 0.39 | 0.47 | 0.36 | 0.08 | 0.13 | 0.07 | 0.00 | 0.00 |
| Inventory Turnover | 0.87 | 0.87 | 0.79 | 3.03 | 3.34 | 5.65 | 1.20 | 3.69 | 3.26 | 27.42 | — |
| Days Sales Outstanding | — | 161.83 | 183.62 | 223.70 | 138.43 | 166.11 | 94.86 | 60.91 | 206.05 | 1778.02 | 26766.67 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | 126.0% | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $2M | $518244 | $123858 | $93054 | $72854 | $59384 | $46240 | $35314 | $25760 | $22342 |
Imminent liquidity and solvency
Based on recent market data, RedHill trades at a P/S multiple of 0.56, which appears to reflect deep investor skepticism regarding the company's ability to achieve profitability or sustain its current commercial operations without significant further dilution or asset divestiture in the near term.
The lack of a meaningful P/E or EV/EBITDA multiple underscores that the market is currently pricing the equity as a distressed asset rather than a growth-oriented pharmaceutical firm. Investors should monitor whether this valuation floor holds as the company approaches critical liquidity thresholds, as the current multiple suggests the market assigns little value to the long-term pipeline potential.
According to quarterly filings, the company's cash conversion cycle has reached an extreme 2,198 days, driven by bloated inventory and extended receivable periods that suggest significant friction in converting product sales into actual cash to fund ongoing research and development activities.
The exceptionally high DSO and DIO figures indicate that RedHill is struggling to collect payments from wholesalers and move product through the channel effectively. This inefficiency exacerbates the company's cash burn, as capital remains trapped in working capital rather than being deployed to support the commercial sales force.
As reported in recent financial statements, the current ratio has compressed to 0.56, signaling that the company's short-term assets are insufficient to cover its immediate liabilities, which warrants further investigation into the firm's ability to maintain operations without an urgent capital infusion.
The quick ratio of 0.42 further highlights a reliance on inventory that may not be easily liquidated at book value, leaving the company with a very thin margin for error. This liquidity profile suggests that the firm is highly vulnerable to any disruption in revenue or unexpected increases in operating expenses.
Investors frequently misapply the P/S ratio to RedHill, which obscures the reality that the company's revenue is heavily burdened by gross-to-net adjustments and royalty obligations that render top-line figures a poor proxy for the actual cash-generating capacity of the underlying GI product portfolio.
A more appropriate metric for this business model would be the net cash burn relative to the remaining cash runway, as the P/S ratio fails to account for the high fixed-cost structure and the negative operating margins. Relying on revenue multiples in this context may lead to an overestimation of the company's intrinsic value.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RDHL stock.
RedHill Biopharma Ltd.'s current P/E ratio is -0.1x. The historical average is 0.8x.
Based on historical data, RedHill Biopharma Ltd. is trading at a P/E of -0.1x. Compare with industry peers and growth rates for a complete picture.
RedHill Biopharma Ltd. has 60.3% gross margin and -181.7% operating margin.